BCT 194Alternative Names: BCT194
Latest Information Update: 12 Nov 2016
At a glance
- Originator Novartis
- Class Antipsoriatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Psoriasis in Austria (Topical, Cream)
- 30 Nov 2006 Phase-I clinical trials in Psoriasis in Austria (Topical)